Overview of novel therapeutic targets for asthma and chronic obstructive pulmonary disease

References

• Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 170(8), 836–844 (2004).
   PubMed Web of Science ®Google Scholar
• Hamid Q. Effects of steroids on inflammation and cytokine gene expression in airway inflammation. J. Allergy Clin. Immunol. 112(3), 636–638 (2003).
   Google Scholar
• Johnson M. Effects of β2-agonists on resident and infiltrating inflammatory cells. J. Allergy Clin. Immunol. 110(6 Suppl.), S282–S290 (2002).
   PubMedGoogle Scholar
• Martin RJ. Considering therapeutic options in the real world. J. Allergy Clin. Immunol. 112(5 Suppl.), S112–S115 (2003).
   Google Scholar
• Passalacqua G, Albano M, Canonica GW et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 55(1), 16–33 (2000).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 23(1), 11–33 (2000).
   PubMed Web of Science ®Google Scholar
• Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur. J. Clin. Pharmacol. 61(3), 203–208 (2005).
   PubMed Web of Science ®Google Scholar
• Karin M. New twist in the gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93, 487–490 (1998).
   PubMed Web of Science ®Google Scholar
• Vayssiere BM, DuPont S, Choquart A et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol. Endocrinol. 11, 1245–1255 (1997).
   PubMed Web of Science ®Google Scholar
• Larsen BB, Nielsen LP, Engelstatter R, Steinijans V, Dahl R. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 58(3), 207–212 (2003).
   PubMed Web of Science ®Google Scholar
• Dockhorn RJ, Baumgartner RA, Leff JA et al. Comparison of the effects of intravenous and oral montelukast on airway function: a double-blind, placebo-controlled, three period, crossover study in asthmatic patients. Thorax 55(4), 260–265 (2000).
   PubMed Web of Science ®Google Scholar
• Grzelewska-Rzymowska I. Clinical aspects of anti-inflammatory action of antihistamines. Pol. Merkuriusz Lek. 14(84), 634–638 (2003).
   Google Scholar
• Di Lorenzo G, Pacor ML, Pellitteri ME et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin. Exp. Allergy 34(8), 1329 (2004).
   Google Scholar
• Gamble E, Grootendorst DC, Brightling CE et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 168(8), 976–982 (2003).
   PubMed Web of Science ®Google Scholar
• Compton CH, Gubb J, Nieman R et al. International Study Group. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358(9278), 265–270 (2001).
   Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the new PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297(1), 267–279 (2001).
   PubMed Web of Science ®Google Scholar
• Hersperger R, Buchheit KH, Cammisuli S et al. A locally active anti-inflammatory macrolide (MLD987) for inhalation therapy of asthma. J. Med. Chem. 23, 47(20), 4950–4957 (2004).
   Google Scholar
• Sano Y, Suzuki N, Yamada H et al. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J. Allergy Clin. Immunol. 111(5), 958–966 (2003).
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB Jr, Su JQ et al. Treatment of allergic asthma with monoclonal antiIgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 341(26), 1966–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Corren J, Diaz-Sanchez D, Saxon A et al. Effects of omalizumab, a humanized monoclonal antiIgE antibody, on nasal reactivity to allergen and local Ig synthesis. Ann. Allergy Asthma Immunol. 93(3), 243–248 (2004).
   Google Scholar
• Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized antiIgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J. Allergy Clin. Immunol. 111(1), 87–90 (2003).
   PubMed Web of Science ®Google Scholar
• Reddy MP, Kinney CA, Chaikin MA et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164(4), 1925–1933 (2000).
   PubMed Web of Science ®Google Scholar
• Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352(9134), 1109–1113 (1998).
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2144–2148 (2000).
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Corren J et al. IL-4R Asthma Study Group Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107(6), 963–970 (2001).
   PubMed Web of Science ®Google Scholar
• Bryan SA, O’Connor BJ, Matti S et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248), 2149–2153 (2000).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol. Immunopathol. (Madr.) 31(5), 270–277 (2003).
   PubMedGoogle Scholar
• Basomba A, Tabar AI, de Rojas DH et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J. Allergy Clin. Immunol. 109(6), 943–948 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease molecular and cellular mechanisms. Eur. Respir. J. 22, 672–688 (2003).
   PubMed Web of Science ®Google Scholar
• Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163, 1304–1309 (2001).
   PubMed Web of Science ®Google Scholar
• Culpitt SV, Rogers DF, Shah P et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167, 24–31 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Ito K, Adcock IM. Costicosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363, 731–733 (2004).
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Masuda K, Kato K et al. Leukotriene B4 receptor: cloning and intracellular signaling. Am. J. Respir. Crit. Care Med. 161, S51–S55 (2000).
   Web of Science ®Google Scholar
• Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 58(4), 294–298 (2003).
   PubMed Web of Science ®Google Scholar
• Beeh KM, Kornmann O, Barnes PJ et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin-8 and leukotriene B4. Chest 123(4), 1240–1247 (2003).
   PubMed Web of Science ®Google Scholar
• Hill AT, Bayley D, Stokley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 160(3), 893–898 (1999).
   PubMed Web of Science ®Google Scholar
• Kilfeather S. 5-lipoxygenase inhibitors for the treatment of COPD. Chest 121, S197–S200 (2002).
   PubMed Web of Science ®Google Scholar
• Lee E, Lindo T, Kilfeather S. Reversal for human neutrophil survival by leukotriene B4 receptor blockade and 5-lipoxygenase activating protein inhibitors. Am. J. Respir. Crit. Care Med. 160(6) 2079–2085 (1999).
   PubMed Web of Science ®Google Scholar
• Gompetz S, Stockley RA. A randomized, placebo-controlled trial of leukotriene syntesis inhibitor in patients with COPD. Chest 122(1), 289–294 (2002).
   Google Scholar
• Kemeny DM, Vyas B, Vukmanovich-Stejie M et al. CD8+ T-cell subsets and chronic obstructive pulmunary desease. Am. J. Respir. Crit. Care Med. 160, S33–S37 (1999).
   Google Scholar
• Saetta M, Baraldo S, Fabbri LM et al. CD8 cell in the lungs of smokers with COPD. Am. J. Respir. Crit. Care Med. 160, 711–717 (1999).
   PubMed Web of Science ®Google Scholar
• Frankenberger M, Menzel M, Bets R et al. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. Clin. Exp. Immunol. 138(3), 507–516 (2004).
   PubMed Web of Science ®Google Scholar
• Tsoumakidou M, Tzanakis N, Stafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir. Med. 97(8), 863–871 (2003).
   PubMed Web of Science ®Google Scholar
• De Boer WI. Potential new drugs for therapy of chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 12(7), 1067–1086 (2003).
   PubMed Web of Science ®Google Scholar
• Buhling F, Tholert G, Kaiser D et al. Increased released of transforming growth factor (TGF)-β1, TGF-β2, and chemoattractant mediators in pneumonia. J. Interferon Cytokine Res. 18(3), 271–278 (1999)
   Google Scholar
• Bagley CJ, Woodcock JM, Lopez AF. The structural and functional basis of cytokine activation. Blood 89, 1471–1482 (1997).
   PubMed Web of Science ®Google Scholar
• Monfardini C, Kieber Emmons T, Williams WV et al. Recombinant antibodies in bioactive peptide design. J. Biol. Chem. 270, 6628–6638 (1995).
   Google Scholar
• Von Feldt JM, Monfardini C, Fish S et al. Development of GM-CSF antagonist peptides. Pept. Res. 6, 20–32 (1995).
   Google Scholar
• De Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J. Allergy Clin. Immunol. 102, 165–169 (1998).
   PubMed Web of Science ®Google Scholar
• Kapp U, Yeh WC, Mark TW et al. Interleukin-13 is secreted by and stimulates the grow of Hodkin and Reed Stenberg cells. J. Exp. Med. 189, 1939–1946 (1999).
   PubMed Web of Science ®Google Scholar
• Johannson B, Ingvarsson S, Borrebaeck CA. Human interdigitating dendritic cells induce isotype switching and IL 13 dependent production in CD40- activated naive B-cells. J. Immunol. 164, 1847–1854 (2000).
   Google Scholar
• Chiaramonte MG, Donaldson DD, Wynn TA. An IL13 inhibitor blocks the development of haepatic fibrosis during a T-helper type 2 inflammatory response. J. Clin. Invest. 104, 777–785 (1999).
   PubMed Web of Science ®Google Scholar
• Pajkrt D, Camoglio L, van Deventer SI et al. Attenuation of pro-inflammatory response by recombinant human IL-10 in human endotoxiemia: effect of recombinant human IL-10 administration. J. Immunol. 158, 3971–3977 (1997).
   Google Scholar
• Bonfield TL, Konstan MW, Berger M. Interleukin-10 suppresses IL-8 secretion by bronchial epitelial cells. Pediatr. Pulmonol. 517, 286 (1998).
   Google Scholar
• Nelson DR, Lauwers GY, Lau JY et al. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatits C; a pilot trial of interferon nonresponsders. Gastroenterology 118, 655–660 (2000).
   PubMed Web of Science ®Google Scholar
• Weinberger B, Heck DE, Laskin DL, Laskin JD. Nitric oxide in the lung: therapeutic and cellular mechanism of action. Pharmacol. Ther. 84, 401–411 (1999).
   PubMed Web of Science ®Google Scholar
• Li T, Molteni A, Latkovich P et al. Vitamin A depletion induced by cigarette smoke is associated with the development of emphysema in rats. J. Nutr. 133(8), 2629–2634 (2003).
   PubMed Web of Science ®Google Scholar
• Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase induced pulmonary emphysema in rats. Nature Med. 3, 675–677 (1997).
   PubMed Web of Science ®Google Scholar
• Maenee WI. Oxidants/antioxidants and COPD. Chest 117, S303–S317 (2000).
   Google Scholar
• Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322, 1271–1274 (2001).
   PubMed Web of Science ®Google Scholar
• Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Anti-oxidant therapy a new pharmacological approach in shock, inflammation and ischaemia/reperfusion injury. Pharmacol. Rev. 53, 135–159 (2001).
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Capelli A et al. Increased expression of NF-κB in bronchial biopsies from snokers and patient with COPD. Eur. Respir. J. 20, 556–563 (2002).
   PubMed Web of Science ®Google Scholar
• Castro AC, Dang LC, Soucy F et al. Novel IKK inhibitors: β-carbolines. Bioorg. Med. Chem. Lett. 13, 2419–2422 (2003).
   PubMed Web of Science ®Google Scholar
• Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R. Differential IKK activation and IkBa degradation by interleukin-1b and tumor necrosis factor-α in human U937 monocytic cells: evidence from additional regulatory step in kB-dependent transcription. J. Biol. Chem. 274, 19965–19972 (1999).
   PubMedGoogle Scholar
• Kumar S, Boehm J, Lee JC. P38 MAPKs: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Rev. Drug Discov. 2, 717–726 (2003).
   PubMed Web of Science ®Google Scholar
• Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 10, 207–213 (2003).
   PubMed Web of Science ®Google Scholar
• Shapiro SD. Animal models for chronic obstructive pulmonary disease. Age of klotho and malboro mice. Am. J. Respir. Cell. Mol. Biol. 22, 4–7 (2000).
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Polentarutti N, Borsatti A et al. Upregulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by INFγ in human neutrophils. J. Immunol. 162, 474–479 (1999).
   PubMed Web of Science ®Google Scholar
• Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160, S29–S32 (1999).
   PubMed Web of Science ®Google Scholar
• Hesselgesser J, Ng HP, Liang M et al. Identification and characterizaion of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. 273, 15687–15692 (1998).
   PubMed Web of Science ®Google Scholar
• White JR, Lee JM, Young PR et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8 induced neutrophil migration. J. Biol. Chem. 273, 10095–10098 (1998).
   PubMed Web of Science ®Google Scholar
• Colantonio L, Iellem A, Clissi B et al. Regulation of integrin α6/β1 chemokine receptor CCR1 by interleukin-12 promotes the migration of human Type 1 helper T-cells. Blood 94, 2981–2989 (1999).
   Google Scholar
• Clissi B, D’Ambrosio D, Geginat J et al. Chemokines fail to upregulate β-1integrin dependent adhesion in human Th2 T lymphocytes. J. Immunol. 164, 3293–3300 (2000).
   Google Scholar
• Aggarval A, Baker CS, Evans TW et al. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur. Respir. J. 15, 895–901 (2000).
   Google Scholar
• Peleman RA, Rytila PH, Kips JC et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur. Respir. J. 13, 839–843 (1999).
   PubMed Web of Science ®Google Scholar
• Newman PJ. Switched at birth: a new family of PECAM-1. J. Clin. Invest. 103, 5–9 (1999).
   PubMed Web of Science ®Google Scholar
• Silver MJ, Sutton JM, Hook S et al. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electolytic canine coronary artery model. Circulation 92, 492–499 (1995).
   PubMedGoogle Scholar
• Hayward R, Campbell B, Shin YK et al. Recombinant soluble P-selectin glycoprotein ligand 1 protects against myocardial ischaemia reperfusion injury in cats. Cardiovasc. Res. 41, 65–76 (1999).
   PubMed Web of Science ®Google Scholar
• Kumar A, Villani MP, Patel UK et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model Circulation 99, 1363–1369 (1999).
   PubMed Web of Science ®Google Scholar
• Steckley RA. Neutrophils and protease/ antiprotease imbalance. Am. J. Respir. Crit. Care Med. 160, S49–S52 (1999).
   Google Scholar
• Fujie K, Shinguh A, Yamazaki A, Hatanaka H, Okamoto M, Okuhara M. Inhibiton of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a new neutrophil elastase inhibitor FR901277. Inflamm. Res. 48, 160–167 (1999).
   PubMed Web of Science ®Google Scholar
• Shapiro SD, Senior RM. Matrix metalloproteinases: matrix degradation and more. Am. J. Respir. Cell. Mol. Biol. 20, 1100–1102 (1999).
   PubMed Web of Science ®Google Scholar
• Balvis MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD) a therapeutic role for inhibitors of MMPs. Inflamm. Res. 52, 95–100 (2003).
   Google Scholar
• Hauber HP, Daigneault P, Frenkiel S et al. Niflumic acid and MSI-2216 reduce TNF-α-induced mucin expression in human airway mucosa. J. Allergy Clin. Immunol. 115, 266–271 (2005).
   PubMed Web of Science ®Google Scholar
• Culpitt SV, Rogers DF, Fenwick PS et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58, 942–946 (2003).
   PubMed Web of Science ®Google Scholar